In addition, in triple-negative breast cancer (TNBC), on account of the deletion of CDK12, it can changeover both De nova PARPi resistance and acquired PARPi resistance, regardless of in BRCA wild-type or mutated models [117]. Here, CDK12 is linked to triple-negative breast carcinoma.